Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
Welcome,         Profile    Billing    Logout  
 162 Trials 
1045 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Chiumello, Davide
NCT03939260: ECCO2R - Mechanical Power Study

Recruiting
N/A
15
Europe
Extracorporeal CO2 Removal
University of Milan
ARDS, Human, Extracorporeal CO2 Removal, Mechanical Power
03/21
03/24
NCT03929055: Efficacy of High Velocity Nasal Insufflation

Recruiting
N/A
25
Europe
Physiological assesment
University of Milan
Acute Respiratory Failure, Diaphragmatic Function, Esophageal Pressure
06/21
06/21
NCT03941002: Continuous Evaluation of Diaphragm Function

Recruiting
N/A
25
Europe
Assesment of diaphragm function
University of Milan
Respiration, Artificial, Mechanical Ventilation, Critical Illness
06/21
06/21
BEARDS, NCT03447288: Incidence of Dyssynchronies in Early ARDS

Recruiting
N/A
300
Europe, Canada, RoW
Unity Health Toronto
ARDS, Acute Hypoxemic Respiratory Failure
08/22
08/22
Fernandez, Maria E
NCT03393975 / 2017-000858-18: A Study of BAX 930 in Children, Teenagers, and Adults Born With Thrombotic Thrombocytopenic Purpura (TTP)

Completed
3
52
Europe, Japan, US
TAK-755, rADAMTS13, SHP-655, recombinant ADAMTS13, BAX 930, Standard of care
Baxalta now part of Shire, Takeda Development Center Americas, Inc.
Thrombotic Thrombocytopenic Purpura (TTP)
12/23
05/24
LIMT-2, NCT05070364 / 2021-003665-35: Phase 3 Study to Evaluate the Efficacy and Safety of Peginterferon Lambda for 48 Weeks in Patients With Chronic HDV

Active, not recruiting
3
150
Europe, US, RoW
Peginterferon Lambda-1a, Lambda, Peginterferon Lambda, Pegylated Interferon Lambda
Eiger BioPharmaceuticals, Eiger BioPharmaceuticals, Inc.
Hepatitis Delta Virus
06/24
01/25
BRAVE-AA-PEDS, NCT05723198: A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata

Recruiting
3
595
Europe, Canada, Japan, US, RoW
Baricitinib, LY3009104, Placebo
Eli Lilly and Company
Areata Alopecia, Alopecia, Hypotrichosis, Hair Diseases, Skin Diseases, Pathological Conditions, Anatomical
09/27
08/29
REITAB-2, NCT05204563: Imipenem/Cilastatin-XNW4107 Versus Imipenem/Cilastatin/Relebactam for Treatment of Participants with Bacterial Pneumonia (XNW4107-302, )

Completed
3
450
Europe, US, RoW
Combination of Imipenem/Cilastatin and XNW4107, Imipenem/Cilastatin/Relebactam, Recarbrio
Evopoint Biosciences Inc.
Hospital Acquired Bacterial Pneumonia or Ventilator-Associated Bacterial Pneumonia
09/24
09/24
MOUNTAINEER-03, NCT05253651 / 2021-002672-40: A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

Recruiting
3
400
Europe, Canada, Japan, US, RoW
tucatinib, TUKYSA, ONT-380, ARRY-380, PF-07265792, trastuzumab, Herceptin, bevacizumab, Avastin, cetuximab, Erbitux, oxaliplatin, leucovorin, levoleucovorin, fluorouracil
Seagen, a wholly owned subsidiary of Pfizer, Merck Sharp & Dohme LLC
Colorectal Neoplasms
04/26
07/29
NCT04683003: A Study of TAK-755 in Participants With Congenital Thrombotic Thrombocytopenic Purpura

Recruiting
3
77
Europe, Japan, US, RoW
TAK-755, rADAMTS13; recombinant ADAMTS13; SHP-655; BAX 930
Takeda, Takeda Development Center Americas, Inc., Shire
Thrombotic Thrombocytopenic Purpura (TTP)
03/27
03/27
Phenomenal, NCT03328884 / 2016-002689-30: Evaluation of the Efficacy and Safety of Nal-IRI for Progressing Brain Metastases in Breast Cancer Patients

Completed
2
55
Europe
Irinotecan (CPT-11) liposome, nal-IRI
MedSIR
Breast Cancer Metastatic
08/18
04/25
CAMPFIRE, NCT05999994: A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer

Recruiting
2
105
Europe, Japan, US, RoW
Ramucirumab, LY3009806, Cyclophosphamide, Vinorelbine, Gemcitabine, LY188011, Docetaxel, Abemaciclib, LY2835219, Irinotecan, Temozolomide
Eli Lilly and Company
Neoplasms, Child, Adolescent
05/27
05/27
NCT05440786 / 2021-004734-11: CAMPFIRE: A Study of Abemaciclib (LY2835219) in Participants With Ewing's Sarcoma

Active, not recruiting
2
45
Europe, Japan, US, RoW
Abemaciclib, LY2835219, Irinotecan, Temozolomide
Eli Lilly and Company
Sarcoma, Ewing, Neoplasm Metastasis
01/25
09/28
NCT05606003: Using a Community-level Just-in-Time Adaptive Intervention to Address COVID-19 Testing Disparities

Active, not recruiting
N/A
1280
US
Multi-Level Multi-Component Intervention (MLI), Community Just-In-Time Adaptive Intervention (Community JITAI)
The University of Texas Health Science Center, Houston, National Center for Advancing Translational Sciences (NCATS)
COVID-19
06/22
12/22
NCT04438265: Quadratus Lumborum Type 2 as Chronic Hip Pain Treatment

Completed
N/A
200
Europe
levobupivacaine, chirocane, ultrasound device
Hospital Medina del Campo, Hospital Universitaio Getafe, Hospital Rio Hortega
Hip Arthropathy, Chronic Hip Pain, Ultrasound Therapy; Complications
09/22
06/24
NCT05606016: Examining How a Facilitated Self-Sampling Intervention and Testing Navigation Intervention Influences COVID-19 Testing

Not yet recruiting
N/A
1280
US
Facilitated Self-Sampling Intervention (FSSI), Testing Navigation Intervention (TNI)., Control
The University of Texas Health Science Center, Houston, National Center for Advancing Translational Sciences (NCATS)
COVID-19
01/23
04/23
NCT04431388: Serratus-intercostal Plane Block Versus Quadratus Lumborum Block in Nephrectomy: Randomized Study

Completed
N/A
126
Europe
ultrasound device, device, Levobupivacaine, drug
Hospital Medina del Campo
Kidney Injury
06/23
12/23
NCT05524480: Accelerating the Implementation of a Breast and Cervical Cancer Screening and HPV Vaccination Intervention

Enrolling by invitation
N/A
2000
US
Salud en Mis Manos - Dissemination and Implementation Assistance, SEMM-DIA, Salud en Mis Manos- Usual Implementation Practice, SEMM
The University of Texas Health Science Center, Houston, Centers for Disease Control and Prevention
Cancer Prevention
06/25
09/25
Cunningham, David
NCT03626688 / 2018-001187-33: A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients

Recruiting
3
1000
Europe, Canada, US, RoW
Ralinepag, APD811, Placebo
United Therapeutics
PAH, Pulmonary Hypertension, Pulmonary Arterial Hypertension, Hypertension, Connective Tissue Diseases, Familial Primary Pulmonary Hypertension, Vascular Diseases, Cardiovascular Diseases, Hypertension, Pulmonary, Lung Diseases, Respiratory Tract Disease
12/25
12/25
HERIZON-GEA-01, NCT05152147 / 2021-000296-36: A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers

Active, not recruiting
3
920
Europe, Canada, Japan, RoW
Zanidatamab, ZW25, JZP598, Tislelizumab, Trastuzumab, Herceptin®, Capecitabine, Oxaliplatin, Cisplatin, 5-Fluorouracil
Jazz Pharmaceuticals, BeiGene
Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma
05/25
05/26
ECHELON-3, NCT04404283 / 2020-002686-33: Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL

Hourglass Jan 2023 - Dec 2023 : From:ECHELON-3 trial in combination with brentuximab vedotin and rituximab for r/r DLBCL
Active, not recruiting
3
241
Europe, Canada, US, RoW
Brentuximab vedotin, Rituximab, Lenalidomide, Placebo
Seagen, a wholly owned subsidiary of Pfizer
Diffuse Large B-cell Lymphoma
11/25
11/25
MOUNTAINEER-03, NCT05253651 / 2021-002672-40: A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

Recruiting
3
400
Europe, Canada, Japan, US, RoW
tucatinib, TUKYSA, ONT-380, ARRY-380, PF-07265792, trastuzumab, Herceptin, bevacizumab, Avastin, cetuximab, Erbitux, oxaliplatin, leucovorin, levoleucovorin, fluorouracil
Seagen, a wholly owned subsidiary of Pfizer, Merck Sharp & Dohme LLC
Colorectal Neoplasms
04/26
07/29
LEGEND, NCT02060656 / 2012-002620-32: Phase II Study Comparing LR-GEM to R-GEM-P in Second-line Treatment of Diffuse Large B-cell Lymphoma

Active, not recruiting
2
92
Europe
Gemcitabine, Methylprednisolone, Rituximab, Cisplatin, Lenalidomide
Royal Marsden NHS Foundation Trust, Celgene Corporation
Diffuse Large B-Cell Lymphoma
02/18
08/23
NCT03892746: Improving SCI Rehabilitation Interventions by Retraining the Brain

Completed
1/2
47
US
Active tDCS + task oriented practice, Sham tDCS + task oriented practice
The Cleveland Clinic, United States Department of Defense
Cervical Spinal Cord Injruy
09/24
10/24
WAKING, NCT04166721: WaKING: Wnt and checKpoint INhibition in Gastric Cancer

Active, not recruiting
1/2
52
Europe
Atezolizumab, DKN-01
Royal Marsden NHS Foundation Trust
Metastatic Esophageal Cancer, Metastatic Gastric Cancer
03/25
12/25
Iintune-1, NCT04420884 / 2022-000528-39: A Study of Dazostinag as Single Agent and Dazostinag in Combination With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors

Active, not recruiting
1/2
374
Europe, Canada, Japan, US, RoW
Dazostinag, TAK-676, Pembrolizumab, Platinum, 5-fluorouracil
Takeda, Takeda Development Center Americas, Inc. (TDC Americas)
Solid Neoplasms
01/26
01/26
FIH, NCT04104776 / 2020-004952-14: A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

Recruiting
1/2
275
Europe, US, RoW
Tulmimetostat, DZR123, Enzalutamide
Novartis Pharmaceuticals
Advanced Solid Tumor, Diffuse Large B Cell Lymphoma, Lymphoma, T-Cell, Mesothelioma, Malignant, Prostatic Neoplasms, Castration-Resistant, Endometrial Cancer, Ovarian Clear Cell Carcinoma, Metastatic Castration-resistant Prostate Cancer
02/30
02/30
NCT03840460: A Prospective Translational Tissue Collection Study in Early and Advanced Pancreatic Ductal Adenocarcinoma and Pancreatic Neuroendocrine Tumours to Enable Further Disease Characterisation and the Development of Potential Predictive and Prognostic Biomarkers

Recruiting
N/A
200
Europe
Royal Marsden NHS Foundation Trust
Pancreatic Adenocarcinoma
01/23
01/23
NCT03857529: Improving Stroke Motor Control With Non-invasive Brain Stimulation and Functional Electrical Stimulation

Recruiting
N/A
15
US
transcranial direct current stimulation and electrical stimulator
MetroHealth Medical Center
Stroke, Rehabilitation, Hand
08/26
08/26
TRACC, NCT04050345: Tracking Mutations in Cell Free Tumour DNA to Predict Relapse in Early Colorectal Cancer

Recruiting
N/A
1000
Europe
Royal Marsden NHS Foundation Trust
Colorectal Cancer
07/29
07/31
MAGnET, NCT06702384: Molecular Analysis of Gastric and OEsophageal Cancers STudy

Withdrawn
N/A
300
Europe
biopsy
Royal Marsden NHS Foundation Trust
Adenocarcinoma Esophagus, Adenocarcinoma of the Stomach, Adenocarcinoma - GEJ, Squamous Cell Car. - Esophagus
05/27
05/30
NCT05866003: tDCS + CCFES-mediated Functional Task Practice for Post-stroke Upper Extremity Hemiplegia

Recruiting
N/A
63
US
Active conventional tDCS montage plus CCFES, Active unconventional tDCS montage plus CCFES, Sham tDCS plus CCFES, CCFES with Occupational Therapy
MetroHealth Medical Center
Stroke, Upper Extremity Paresis, Hemiplegia
04/28
04/28
Fracchiolla, Nicola
NCT03250338 / 2017-001600-29: Study Investigating the Efficacy of Crenolanib With Chemotherapy vs Chemotherapy Alone in R/R FLT3 Mutated AML

Recruiting
3
322
Europe, Canada, US
Crenolanib, Crenolanib besylate, Cytarabine, Mitoxantrone, Placebo Oral Tablet, Fludarabine, Idarubicin, G-CSF
Arog Pharmaceuticals, Inc.
Relapsed/Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations
10/24
10/24
NCT04342962 / 2020-001543-94: Tagraxofusp in Patients With CD123+ or With BPDCN-IPh-like Acute Myeloid Leukemia

Terminated
2
25
Europe
tagraxofusp
Gruppo Italiano Malattie EMatologiche dell'Adulto, Stemline Therapeutics, Inc., Fondazione GIMEMA (Gruppo Italiano Malattie EMatologiche dell'Adulto) Franco Mandelli Onlus
Acute Myeloid Leukemia
01/24
01/24
NCT05306301 / 2022-000633-17: Ponatinib Plus Chemotherapy in Acute Lymphoblastic Leukemia Patients

Recruiting
2
32
Europe
Ponatinib
Gruppo Italiano Malattie EMatologiche dell'Adulto, Incyte Biosciences International Sàrl, Docteur-Yersin 12, 1110 Morges, Switzerland, FONDAZIONE GIMEMA
Chemotherapy, Leukemia, Acute Lymphoblastic
02/25
07/28
1621-QLG-LG, NCT03755856: Long-term Outcomes for Acute Myeloid Leukemia Patients

Recruiting
N/A
343
Europe, RoW
Questionnaire
Gruppo Italiano Malattie EMatologiche dell'Adulto, European Organisation for Research and Treatment of Cancer - EORTC
Acute Myeloid Leukemia
06/21
12/22
NCT04352556: COVID19-hematological Malignancies: the Italian Hematology Alliance

Recruiting
N/A
250
Europe
Ospedale di Circolo - Fondazione Macchi
SARS-CoV-2 Infection, Hematological Malignancies
10/22
10/22
GIMEMA 2320, NCT04589728: Prospective and Retrospective Observational Evaluation of Real World Outcome of Unfit AML Patients Treated With the Combination Venetoclax Plus Hypomethylating Agents, Under the Italian Law No.648/96

Recruiting
N/A
104
Europe
Venetoclax plus HMA
Gruppo Italiano Malattie EMatologiche dell'Adulto
Acute Myeloid Leukemia
12/22
12/23
NCT04460950: Observational Study for the Evaluation of Incidence of Familial AML/MDSs in Patients With Myeloid Neoplasms

Recruiting
N/A
237
Europe
Gruppo Italiano Malattie EMatologiche dell'Adulto
Acute Myeloid Leukemia, Familial Acute Myeloid Leukemia, Myelodysplastic Syndromes
03/25
03/25
NCT03318770: Post-Frontline Sequential Treatment of Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Recruiting
N/A
60
Europe
Dasatinib and blinatumomab
Gruppo Italiano Malattie EMatologiche dell'Adulto
Acute Lymphoblastic Leukemia
05/24
05/24
IMPACT STREAM, NCT06459024: Master Framework For Relapse or Refractory Acute Myeloid Leukemia

Recruiting
N/A
4000
Europe
Registration into the STREAM platform
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS, Hospital Vall d'Hebron, Cyprus Institute of Neurology and Genetics, European LeukemiaNet, Fundacion Para La Investigacion Hospital La Fe, Ostedusche Hematology and Oncology Study Group, Ospedale Pediatrico Bambin Gesù, Czech Lymphoma Study Group, Charite University, Berlin, Germany, Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León, University of Bologna, Hannover Medical School, German Society for Pediatric Oncology and Hematology GPOH gGmbH, Toscana Life Sciences Sviluppo s.r.l., Lithuanian University of Health Sciences, Gruppo Italiano Malattie EMatologiche dell'Adulto, Time.Lex
Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory
07/32
07/32
Drenth, Joost PH
CAMARO, NCT02900443: Mycophenolate Mofetil Versus Azathioprine in Treatment Naive Autoimmune Hepatitis

Active, not recruiting
4
70
Europe
Mycophenolate mofetil, Azathioprine
Radboud University Medical Center, Leiden University Medical Center
Autoimmune Hepatitis
06/23
06/23
NATiV3, NCT04849728: A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( )

Recruiting
3
1000
Europe, Canada, US, RoW
IVA337, Lanifibranor, Placebo
Inventiva Pharma
NASH - Nonalcoholic Steatohepatitis
09/25
09/26
POSITANO, NCT05281328 / 2021-003764-27: A Trial to Assess the Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With PLD

Active, not recruiting
2/3
71
Europe, US
CAM2029, octreotide subcutaneous depot, Placebo
Camurus AB, Camurus AB
Polycystic Liver Disease
02/25
08/27
ATLAS, NCT05500157: Assessment of Treatment With Laparoscopic Fenestration or Aspiration Sclerotherapy for Large Symptomatic Hepatic Cysts

Recruiting
N/A
70
Europe
aspiration sclerotherapy versus laparoscopic fenestration
Radboud University Medical Center
Liver Cyst, Polycystic Liver Disease, Autosomal Dominant Polycystic Kidney, Autosomal Dominant Polycystic Liver Disease
10/23
10/24
NCT02173080: Development and Assessment of The Polycystic Liver Disease Questionnaire (PLD-Q).

Completed
N/A
594
US
PLD-Q
Mayo Clinic
Polycystic Liver Disease
03/24
03/24
PLD, NCT04645251: Polycystic Liver Disease Registry (UK)

Recruiting
N/A
500
Europe
Portsmouth Hospitals NHS Trust, Radboud University Medical Center
Polycystic Liver Disease
12/30
12/30
Agostoni, Carlo
PROBIOS2021, NCT06052540: Probiotic Supplementation in Children Affected by Upper Respiratory Infections

Active, not recruiting
N/A
128
Europe
Probiotic supplement, Ofmom SynterAct BIMBI, Placebo
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Upper Respiratory Tract Infection
06/23
06/24
Zinzani, Pier Luigi
BRUIN CLL-313, NCT05023980: A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Active, not recruiting
3
250
Europe, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Bendamustine, Treanda, Treakisym, Ribomustin, Levact, Rituximab, Rituxan, MabThera, Truxima, Riabni, Ruxience
Loxo Oncology, Inc., Eli Lilly and Company
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
05/25
08/26
BRUIN-MCL-321, NCT04662255 / 2020-004553-72: Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)

Recruiting
3
500
Europe, Canada, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib, Imbruvica, Acalabrutinib, Calquence, Zanubrutinib, Brukinsa
Loxo Oncology, Inc., Eli Lilly and Company
Lymphoma, Mantle-Cell
01/27
04/28
ECHELON-3, NCT04404283 / 2020-002686-33: Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL

Hourglass Jan 2023 - Dec 2023 : From:ECHELON-3 trial in combination with brentuximab vedotin and rituximab for r/r DLBCL
Active, not recruiting
3
241
Europe, Canada, US, RoW
Brentuximab vedotin, Rituximab, Lenalidomide, Placebo
Seagen, a wholly owned subsidiary of Pfizer
Diffuse Large B-cell Lymphoma
11/25
11/25
BRUIN CLL-322, NCT04965493 / 2021-000043-49: A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Active, not recruiting
3
600
Europe, Canada, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Venetoclax, Venclexta, Venclyxto, Rituximab, Rituxan, MabThera, Truxima, Riabni, Ruxience
Loxo Oncology, Inc., Eli Lilly and Company
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
04/26
01/27
BRUIN-CLL-314, NCT05254743 / 2021-003206-41: A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Active, not recruiting
3
650
Europe, Canada, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib
Loxo Oncology, Inc., Eli Lilly and Company
Chronic Lymphocytic Leukemia, Leukemia, Lymphocytic, Leukemia, B-cell, Small Lymphocytic Lymphoma
06/25
01/28
RITZ, NCT05735834: Comparison Between Rituximab Plus Zanubrutinib Versus Rituximab Monotherapy in Untreated SMZL Patients

Recruiting
3
120
Europe
Rituximab, Truxima, Zanubrutinib, Brukinsa
International Extranodal Lymphoma Study Group (IELSG)
Splenic Marginal Zone Lymphoma
05/29
05/29
NCT04442022 / 2020-000605-84: A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) with or Without Selinexor in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma

Recruiting
2/3
501
Europe, US, RoW
Selinexor (combination therapy), Placebo matching for Selinexor (combination therapy), Rituximab (combination therapy), Gemcitabine (combination therapy), Dexamethasone (combination therapy), Cisplatin (combination therapy), Selinexor (continuous therapy), Placebo matching for Selinexor (continuous therapy)
Karyopharm Therapeutics Inc
Relapsed/refractory Diffuse Large B-cell Lymphoma
12/25
12/25
LORELY, NCT06918912 / 2022-001147-24: Study of Loncastuximab Tesirine in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) or High-Grade B-Cell Lymphoma (HGBCL) Following CAR-T Therapy Failure

Recruiting
2
50
Europe
Loncastuximab Tesirine (Anti-CD19 Antibody-Drug Conjugate)
Istituto Clinico Humanitas
Diffuse Large B-Cell Lymphoma, High-grade B-cell Lymphoma (HGBCL), B-Cell Lymphoma Treatment, Relapsed or Refractory Lymphoma
03/25
06/27
TELLOMAK, NCT03902184 / 2018-003969-33: IPH4102 Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma

Checkmark Preliminary efficacy data from TELLOMAK trial for Sezary syndrome at ASH 2022
Dec 2022 - Dec 2022: Preliminary efficacy data from TELLOMAK trial for Sezary syndrome at ASH 2022
Checkmark Data from stage 2 cohort of TELLOMAK trial for mycosis fungoides
Sep 2022 - Sep 2022: Data from stage 2 cohort of TELLOMAK trial for mycosis fungoides
Checkmark Preliminary efficacy data from stage 1 of TELLOMAK trial for mycosis fungoides at ICML 2021
More
Active, not recruiting
2
170
Europe, US
IPH4102, lacutamab
Innate Pharma
Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Mycosis Fungoides/Sezary Syndrome
10/23
01/26
SGN35-032, NCT04569032 / 2020-002336-74: A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression

Active, not recruiting
2
82
Europe, US, RoW
brentuximab vedotin, ADCETRIS, cyclophosphamide, doxorubicin, prednisone
Seagen, a wholly owned subsidiary of Pfizer
Peripheral T-cell Lymphoma
05/24
12/25
DALY 2-EU, NCT04844866 / 2020-003908-14: Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients

Active, not recruiting
2
168
Europe, RoW
MB-CART2019.1, R-GemOx or BR plus polatuzumab vedotin, Rituximab, Gemcitabine, Oxaliplatin, Polatuzumab vedotin, Bendamustine, Rituximab
Miltenyi Biomedicine GmbH, ICON plc
Diffuse Large B-cell Lymphoma
01/25
07/29
FIL_MOZART, NCT06492837: Study With Mosunetuzumab and Zanubrutinib in R/R Follicular Lymphoma Patients

Not yet recruiting
2
56
Europe
Mosunetuzumab in combination with Zanubrutinib, LUNSUMIO in combination with BRUSINKA
Fondazione Italiana Linfomi - ETS
Follicular Lymphoma
09/28
09/33
NCT06854653: A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCL

Recruiting
2
115
Europe, US, RoW
PTX-100
Prescient Therapeutics, Ltd.
CTCL
01/28
06/28
MOLTO, NCT04082897 / 2018-005028-40: ObinutuzuMab AtezOlizumab and VenetocLax in RichTer transfOrmation

Active, not recruiting
2
28
Europe
Obinutuzumab 25 MG/ML [Gazyva], Atezolizumab 60 MG/ML [Tecentriq], Venetoclax Oral Tablet
Niguarda Hospital
CLL Transformation
09/26
12/26
FIL_Tisle-HL, NCT05977673: Efficacy and Safety of Frontline Tislelizumab in Patients With de Novo Hodgkin Lymphoma Unsuitable for Standard Frontline Chemotherapy

Recruiting
2
28
Europe
Tislelizumab
Fondazione Italiana Linfomi - ETS
Hodgkin Lymphoma
11/27
11/29
SIDNEY, NCT04669171 / 2020-003999-40: A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma

Recruiting
1/2
60
Europe, US
EO2463, lenalidomide, Revlimid, rituximab, MabThera
Enterome
Follicular Lymphoma, Marginal Zone Lymphoma
05/26
05/32
ALPHA-2, NCT04416984: Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (ALPHA2)

Recruiting
1/2
160
Europe, Canada, US, RoW
ALLO-501A, ALLO-647, Fludarabine, Cyclophosphamide
Allogene Therapeutics
Relapsed or Refractory Large B Cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small Lymphocytic Lymphoma
01/25
05/29
FIH, NCT04104776 / 2020-004952-14: A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

Recruiting
1/2
275
Europe, US, RoW
Tulmimetostat, DZR123, Enzalutamide
Novartis Pharmaceuticals
Advanced Solid Tumor, Diffuse Large B Cell Lymphoma, Lymphoma, T-Cell, Mesothelioma, Malignant, Prostatic Neoplasms, Castration-Resistant, Endometrial Cancer, Ovarian Clear Cell Carcinoma, Metastatic Castration-resistant Prostate Cancer
02/30
02/30
NCT02576496: Study of Tinostamustine, First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies

Completed
1
106
Europe, US
Tinostamustine, EDO-S101
Mundipharma Research Limited
Hematological Malignancies, Multiple Myeloma, Hodgkin's Lymphoma, Cutaneous T Cell Lymphoma
05/23
11/23
POSS, NCT06734078: An Italian Multicenter Retrospective Observational Study to Assess the Clinical Characteristics and the Outcome of Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma Treated with Polatuzumab Vedotin Plus Rituximab (± Bendamustine) Under Named Patient Programme

Active, not recruiting
N/A
100
Europe
IRCCS Azienda Ospedaliero-Universitaria di Bologna
DLBCL - Diffuse Large B Cell Lymphoma
12/25
12/25
VAX4FRAIL, NCT04848493: National Project on Vaccines, COVID-19 and Frail Patients

Recruiting
N/A
1300
Europe
COVID-19 vaccines
Azienda Unità Sanitaria Locale Reggio Emilia, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Istituto Clinico Humanitas, IRCCS San Raffaele, Regina Elena Cancer Institute, Istituto Nazionale per le Malattie Infettive "Lazzaro Spallanzani" IRCCS, University of Roma La Sapienza, Fondazione IRCCS Policlinico San Matteo di Pavia, Istituti Fisioterapici Ospitalieri, Istituto Tumori Giovanni Paolo II, BARI, Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta, IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy, IRCCS Azienda Ospedaliero-Universitaria di Bologna
COVID-19, Solid Tumor, Hematologic Diseases, Neurologic Disorder, Rheumatic Diseases
07/21
04/22
LYMPH-OS, NCT06814925: Italian Study of Patients with Lymphoma

Recruiting
N/A
1500
Europe
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Lymphoma
08/26
08/26
RETRO-LYMPH, NCT06781437: Retrospective Observational Study of Italian Cohort of Lymphoma Patients

Recruiting
N/A
5500
Europe
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Lymphoproliferative Syndrome, Autoimmune, Lymphoma
12/27
12/27
PRIMICI, NCT06781450: Study in Patients with Relapsed/refractory Primary Mediastinal Lymphoma Treated with Pembrolizumab or Nivolumab in Combination with Brentuximab Vedotin in a Real-life Context

Recruiting
N/A
50
Europe
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Primary Mediastinal B Cell Lymphoma
12/25
12/25
PIXBRIDGE, NCT06760936: Pixantrone as Bridging Therapy to Allogenic Transplant or CAR-T Cell Therapy in DLBCL Patients

Active, not recruiting
N/A
15
Europe
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Diffuse Large B Cell Lymphoma (DLBCL)
12/25
12/25
MEPI-AGE, NCT06761274: Study of Epigenetic and Inflammatory Markers of Accelerated Biological Ageing in the Follow up of Patients With Hodgkin's Lymphoma

Recruiting
N/A
200
Europe
peripheral blood sampling
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Hodgkin Lymphoma in Remission
09/25
09/25
SilOs, NCT06720870: An Italian Multicenter Retrospective Observational Study to Assess Effectiveness and Safety of Siltuximab for Patients with Castleman's Disease Treated in Italy in a Real-life Context

Recruiting
N/A
65
Europe
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Castleman Disease
01/25
01/25
AMICO, NCT06814405: Safety and Feasibility of a Multidisciplinary Programme of Integrated Hospital-home Management with Early Discharge of Patients with Haematological Malignancies Undergoing High-dose Chemotherapy in Hospital

Recruiting
N/A
100
Europe
Home patient management, Hospital patient management
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Haematological Malignancy
12/25
12/25
NCT03797170: Design of New Personalized Therapeutic Approaches for Diffuse Large B-cell Lymphoma

Active, not recruiting
N/A
50
Europe
Gut microbiota samples
University of Bologna
Diffuse Large B Cell Lymphoma
07/23
12/23
NCT06299553: Study to Evaluate the Effectiveness of Tafasitamab in Combination With Lenalidomide Followed by Tafasitamab Monotherapy in Relapsed or Refractory Diffuse Large B-cell Lymphoma Non-transplant Eligible Patients in Italy (PRO-MIND)

Recruiting
N/A
200
Europe
Incyte Biosciences Italy S.r.l, Advice Pharma Group srl
DLBCL - Diffuse Large B Cell Lymphoma
06/25
06/27
LNH012, NCT06026644: Health-Related Quality of Life Outcomes in Patients With Aggressive B-Cell Lymphomas Treated With CAR-T Cell Therapy in Real Life

Active, not recruiting
N/A
170
Europe
Gruppo Italiano Malattie EMatologiche dell'Adulto
DLBCL - Diffuse Large B Cell Lymphoma
02/24
04/26
NCT06441214: Retrospective-prospective Study to Evaluate Treatment Management and Outcomes of Patients With Waldenström's Macroglobulinemia (WM) Treated in Italy According to the Zanubrutinib (Brukinsa®) Compassionate Use Program (CUP) and in Common Practice Following Commercial Approval.

Not yet recruiting
N/A
125
Europe
Zanubrutinib
Fondazione Italiana Linfomi - ETS
Waldenström's Macroglobulinemia (WM)
07/26
07/26
HL-SIP, NCT06733987: Immunological Senescence Phenotype as a Resistance Profile to Pembrolizumab in Patients With Relapsed/Refractory Hodgkin's Lymphoma

Recruiting
N/A
40
Europe
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Hodgkin Lymphoma
02/27
02/27
CLIO, NCT06720701: Development of Prognostic Models for Response and Toxicity to CAR-T Cell Therapy in Patients with Relapsed/refractory Non Hodgkin's Lymphoma.

Not yet recruiting
N/A
125
Europe
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Non-Hodgkin Lymphoma
12/26
12/26
ZanOs, NCT06823960: Study to Assess Effectiveness and Safety of Zanubrutinib for Patients with Marginal Zone Lymphoma Treated in Italy Under the Named Patient Program (NPP)

Recruiting
N/A
59
Europe
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Marginal Zone Lymphoma(MZL)
06/25
06/25
FIL_CTCL, NCT06588868: Systemic Therapies in the Treatment of Cutaneous T-cell Lymphoma

Not yet recruiting
N/A
400
Europe
Fondazione Italiana Linfomi - ETS, Takeda
Cutaneous T Cell Lymphoma, Cutaneous T-Cell Lymphoma/Mycosis Fungoides, Cutaneous T-Cell Lymphoma/Sezary Syndrome
07/26
07/26
BRAF, NCT06781515: Assessment of Disease Burden in Hairy Cell Leukemia

Recruiting
N/A
45
Europe
Peripheral and BM blood sample
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Hairy Cell Leukemia
11/25
11/25
FIL_MOGA, NCT06113081: Real World Experience With Mogamulizumab in the Treatment of Cutaneous T-cell Lymphoma

Recruiting
N/A
150
Europe
Fondazione Italiana Linfomi - ETS
Cutaneous T Cell Lymphoma, Cutaneous T-Cell Lymphoma/Mycosis Fungoides, Cutaneous T-Cell Lymphoma/Sezary Syndrome
05/25
07/25
MarZoLyOss, NCT06806488: Study to Assess Clinical Characteristics and Outcome of Patients with Marginal Zone Lymphomas

Recruiting
N/A
160
Europe
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Marginal Zone B Cell Lymphoma
10/25
10/25
Endemato, NCT06851702: Observational Study for the Evaluation of Immune-mediated Endocrinological Adverse Events in Patients with Hematological Malignancies and Subjected to Treatment with Immune-checkpoint Inhibitors

Recruiting
N/A
100
Europe
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Hematological Malignancies
12/25
12/25
ACCELERATE, NCT02817997: International Registry for Patients With Castleman Disease

Recruiting
N/A
1000
US
University of Pennsylvania, EUSA Pharma, Inc., Castleman Disease Collaborative Network, Food and Drug Administration (FDA)
Castleman Disease, Castleman's Disease, Giant Lymph Node Hyperplasia, Angiofollicular Lymph Hyperplasia, Angiofollicular Lymph Node Hyperplasia, Angiofollicular Lymphoid Hyperplasia, GLNH, Hyperplasia, Giant Lymph Node, Lymph Node Hyperplasia, Giant
09/26
09/26
MicroCar, NCT05725720: Role of the Gut Microbiome in the Outcome of Diffuse Large B-Cell Lymphoma Patients Treated With CAR-T Cell Therapy

Recruiting
N/A
90
Europe
Gut microbiome analysis
University of Bologna, Associazione Italiana per la Ricerca sul Cancro, IRCCS Azienda Ospedaliero-Universitaria di Bologna
Diffuse Large B Cell Lymphoma
07/27
12/27
NCT05700149: Integrated Molecular and Clinical Profiling to Improve Disease Characterization and Outcome Prediction in Nodal Marginal Zone Lymphoma

Recruiting
N/A
300
Europe, US, RoW
International Extranodal Lymphoma Study Group (IELSG)
Nodal Marginal Zone Lymphoma
12/26
12/26
Sabatino, Antonio Di
RIDARTII, NCT04587141: Clinical Burden of Anemia in Inflammatory Bowel Disease: Therapeutic Trial

Recruiting
3
300
Europe
Sucrosomial iron, Sideral, Ferric Gluconate, Ferrlecit, Ferric carboxymaltose, Ferinject
IRCCS Policlinico S. Matteo, Italian Group for Inflammatory Bowel Diseases (IG-IBD)
Iron Deficiency Anemia, Inflammatory Bowel Diseases
06/23
06/23
ABX464-105, NCT05507203: ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1

Recruiting
3
612
Europe, Canada, US, RoW
ABX464, Obefazimod, Placebo
Abivax S.A.
Ulcerative Colitis
03/25
04/25
ABTECT, NCT05535946: - Maintenance

Recruiting
3
1050
Europe, Canada, Japan, US, RoW
ABX464, Obefazimod, Placebo
Abivax S.A.
Ulcerative Colitis
01/26
01/30
NCT06598943: A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis

Recruiting
2
140
Europe, Canada, Japan, US, RoW
Eltrekibart, LY3041658, Mirikizumab, LY3074828, Placebo
Eli Lilly and Company
Ulcerative Colitis, Ulcerative Colitis Chronic
12/27
09/28
ENHANCE-CD, NCT06456593: Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease

Recruiting
2
212
Europe, US, RoW
Obefazimod, Placebo
Abivax S.A.
Moderately to Severely Active Crohn Disease
12/26
04/28
NCT05353985 / 2020-005438-14: A Study of TAK-062 in Treatment of Active Celiac Disease in Participants Attempting a Gluten-Free Diet

Completed
2
153
Europe, Canada, US
TAK-062, Simulated Inadvertent Gluten Exposure (SIGE) Gluten-Bar, TAK-062 Placebo, Simulated Inadvertent Gluten Exposure (SIGE) Gluten-free Bar
Takeda
Celiac Disease
11/24
11/24
PROSPER, NCT06505304: AI-enabled Endoscopic Prediction of Post-operative Recurrence in Crohn's Disease

Recruiting
N/A
225
Europe, Canada, RoW
Colonoscopy, Intestinal biopsies, Confocal laser endomicroscopy, Intestinal ultrasound, Stool, Blood, Saliva, Clinical follow-up
University College Cork, The Leona M. and Harry B. Helmsley Charitable Trust
Crohn Disease
10/25
05/26
MONET, NCT06709209: AI-driven Narrow-band Imaging Score for Disease Assessment and Outcome Prediction in Ulcerative Colitis

Recruiting
N/A
300
Europe, Japan, RoW
Colonoscopy after bowel cleansing, Intestinal biopsies, blood sampling, Stool, Clinical follow-up
University College Cork, Olympus
Ulcerative Colitis (UC)
09/26
09/27
SENIOR, NCT05853874: Development of Sustainable Eating Pattern to Limit Malnutrition in Older Adults

Not yet recruiting
N/A
128
NA
Nutrition intervention (dietary protocol), Hospital standard of care
University of Pavia, Fondazione Salvatore Maugeri, Fondazione IRCCS Policlinico San Matteo di Pavia
Malnutrition, Sarcopenia
01/26
01/26
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Chiumello, Davide
NCT03939260: ECCO2R - Mechanical Power Study

Recruiting
N/A
15
Europe
Extracorporeal CO2 Removal
University of Milan
ARDS, Human, Extracorporeal CO2 Removal, Mechanical Power
03/21
03/24
NCT03929055: Efficacy of High Velocity Nasal Insufflation

Recruiting
N/A
25
Europe
Physiological assesment
University of Milan
Acute Respiratory Failure, Diaphragmatic Function, Esophageal Pressure
06/21
06/21
NCT03941002: Continuous Evaluation of Diaphragm Function

Recruiting
N/A
25
Europe
Assesment of diaphragm function
University of Milan
Respiration, Artificial, Mechanical Ventilation, Critical Illness
06/21
06/21
BEARDS, NCT03447288: Incidence of Dyssynchronies in Early ARDS

Recruiting
N/A
300
Europe, Canada, RoW
Unity Health Toronto
ARDS, Acute Hypoxemic Respiratory Failure
08/22
08/22
Fernandez, Maria E
NCT03393975 / 2017-000858-18: A Study of BAX 930 in Children, Teenagers, and Adults Born With Thrombotic Thrombocytopenic Purpura (TTP)

Completed
3
52
Europe, Japan, US
TAK-755, rADAMTS13, SHP-655, recombinant ADAMTS13, BAX 930, Standard of care
Baxalta now part of Shire, Takeda Development Center Americas, Inc.
Thrombotic Thrombocytopenic Purpura (TTP)
12/23
05/24
LIMT-2, NCT05070364 / 2021-003665-35: Phase 3 Study to Evaluate the Efficacy and Safety of Peginterferon Lambda for 48 Weeks in Patients With Chronic HDV

Active, not recruiting
3
150
Europe, US, RoW
Peginterferon Lambda-1a, Lambda, Peginterferon Lambda, Pegylated Interferon Lambda
Eiger BioPharmaceuticals, Eiger BioPharmaceuticals, Inc.
Hepatitis Delta Virus
06/24
01/25
BRAVE-AA-PEDS, NCT05723198: A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata

Recruiting
3
595
Europe, Canada, Japan, US, RoW
Baricitinib, LY3009104, Placebo
Eli Lilly and Company
Areata Alopecia, Alopecia, Hypotrichosis, Hair Diseases, Skin Diseases, Pathological Conditions, Anatomical
09/27
08/29
REITAB-2, NCT05204563: Imipenem/Cilastatin-XNW4107 Versus Imipenem/Cilastatin/Relebactam for Treatment of Participants with Bacterial Pneumonia (XNW4107-302, )

Completed
3
450
Europe, US, RoW
Combination of Imipenem/Cilastatin and XNW4107, Imipenem/Cilastatin/Relebactam, Recarbrio
Evopoint Biosciences Inc.
Hospital Acquired Bacterial Pneumonia or Ventilator-Associated Bacterial Pneumonia
09/24
09/24
MOUNTAINEER-03, NCT05253651 / 2021-002672-40: A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

Recruiting
3
400
Europe, Canada, Japan, US, RoW
tucatinib, TUKYSA, ONT-380, ARRY-380, PF-07265792, trastuzumab, Herceptin, bevacizumab, Avastin, cetuximab, Erbitux, oxaliplatin, leucovorin, levoleucovorin, fluorouracil
Seagen, a wholly owned subsidiary of Pfizer, Merck Sharp & Dohme LLC
Colorectal Neoplasms
04/26
07/29
NCT04683003: A Study of TAK-755 in Participants With Congenital Thrombotic Thrombocytopenic Purpura

Recruiting
3
77
Europe, Japan, US, RoW
TAK-755, rADAMTS13; recombinant ADAMTS13; SHP-655; BAX 930
Takeda, Takeda Development Center Americas, Inc., Shire
Thrombotic Thrombocytopenic Purpura (TTP)
03/27
03/27
Phenomenal, NCT03328884 / 2016-002689-30: Evaluation of the Efficacy and Safety of Nal-IRI for Progressing Brain Metastases in Breast Cancer Patients

Completed
2
55
Europe
Irinotecan (CPT-11) liposome, nal-IRI
MedSIR
Breast Cancer Metastatic
08/18
04/25
CAMPFIRE, NCT05999994: A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer

Recruiting
2
105
Europe, Japan, US, RoW
Ramucirumab, LY3009806, Cyclophosphamide, Vinorelbine, Gemcitabine, LY188011, Docetaxel, Abemaciclib, LY2835219, Irinotecan, Temozolomide
Eli Lilly and Company
Neoplasms, Child, Adolescent
05/27
05/27
NCT05440786 / 2021-004734-11: CAMPFIRE: A Study of Abemaciclib (LY2835219) in Participants With Ewing's Sarcoma

Active, not recruiting
2
45
Europe, Japan, US, RoW
Abemaciclib, LY2835219, Irinotecan, Temozolomide
Eli Lilly and Company
Sarcoma, Ewing, Neoplasm Metastasis
01/25
09/28
NCT05606003: Using a Community-level Just-in-Time Adaptive Intervention to Address COVID-19 Testing Disparities

Active, not recruiting
N/A
1280
US
Multi-Level Multi-Component Intervention (MLI), Community Just-In-Time Adaptive Intervention (Community JITAI)
The University of Texas Health Science Center, Houston, National Center for Advancing Translational Sciences (NCATS)
COVID-19
06/22
12/22
NCT04438265: Quadratus Lumborum Type 2 as Chronic Hip Pain Treatment

Completed
N/A
200
Europe
levobupivacaine, chirocane, ultrasound device
Hospital Medina del Campo, Hospital Universitaio Getafe, Hospital Rio Hortega
Hip Arthropathy, Chronic Hip Pain, Ultrasound Therapy; Complications
09/22
06/24
NCT05606016: Examining How a Facilitated Self-Sampling Intervention and Testing Navigation Intervention Influences COVID-19 Testing

Not yet recruiting
N/A
1280
US
Facilitated Self-Sampling Intervention (FSSI), Testing Navigation Intervention (TNI)., Control
The University of Texas Health Science Center, Houston, National Center for Advancing Translational Sciences (NCATS)
COVID-19
01/23
04/23
NCT04431388: Serratus-intercostal Plane Block Versus Quadratus Lumborum Block in Nephrectomy: Randomized Study

Completed
N/A
126
Europe
ultrasound device, device, Levobupivacaine, drug
Hospital Medina del Campo
Kidney Injury
06/23
12/23
NCT05524480: Accelerating the Implementation of a Breast and Cervical Cancer Screening and HPV Vaccination Intervention

Enrolling by invitation
N/A
2000
US
Salud en Mis Manos - Dissemination and Implementation Assistance, SEMM-DIA, Salud en Mis Manos- Usual Implementation Practice, SEMM
The University of Texas Health Science Center, Houston, Centers for Disease Control and Prevention
Cancer Prevention
06/25
09/25
Cunningham, David
NCT03626688 / 2018-001187-33: A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients

Recruiting
3
1000
Europe, Canada, US, RoW
Ralinepag, APD811, Placebo
United Therapeutics
PAH, Pulmonary Hypertension, Pulmonary Arterial Hypertension, Hypertension, Connective Tissue Diseases, Familial Primary Pulmonary Hypertension, Vascular Diseases, Cardiovascular Diseases, Hypertension, Pulmonary, Lung Diseases, Respiratory Tract Disease
12/25
12/25
HERIZON-GEA-01, NCT05152147 / 2021-000296-36: A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers

Active, not recruiting
3
920
Europe, Canada, Japan, RoW
Zanidatamab, ZW25, JZP598, Tislelizumab, Trastuzumab, Herceptin®, Capecitabine, Oxaliplatin, Cisplatin, 5-Fluorouracil
Jazz Pharmaceuticals, BeiGene
Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma
05/25
05/26
ECHELON-3, NCT04404283 / 2020-002686-33: Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL

Hourglass Jan 2023 - Dec 2023 : From:ECHELON-3 trial in combination with brentuximab vedotin and rituximab for r/r DLBCL
Active, not recruiting
3
241
Europe, Canada, US, RoW
Brentuximab vedotin, Rituximab, Lenalidomide, Placebo
Seagen, a wholly owned subsidiary of Pfizer
Diffuse Large B-cell Lymphoma
11/25
11/25
MOUNTAINEER-03, NCT05253651 / 2021-002672-40: A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

Recruiting
3
400
Europe, Canada, Japan, US, RoW
tucatinib, TUKYSA, ONT-380, ARRY-380, PF-07265792, trastuzumab, Herceptin, bevacizumab, Avastin, cetuximab, Erbitux, oxaliplatin, leucovorin, levoleucovorin, fluorouracil
Seagen, a wholly owned subsidiary of Pfizer, Merck Sharp & Dohme LLC
Colorectal Neoplasms
04/26
07/29
LEGEND, NCT02060656 / 2012-002620-32: Phase II Study Comparing LR-GEM to R-GEM-P in Second-line Treatment of Diffuse Large B-cell Lymphoma

Active, not recruiting
2
92
Europe
Gemcitabine, Methylprednisolone, Rituximab, Cisplatin, Lenalidomide
Royal Marsden NHS Foundation Trust, Celgene Corporation
Diffuse Large B-Cell Lymphoma
02/18
08/23
NCT03892746: Improving SCI Rehabilitation Interventions by Retraining the Brain

Completed
1/2
47
US
Active tDCS + task oriented practice, Sham tDCS + task oriented practice
The Cleveland Clinic, United States Department of Defense
Cervical Spinal Cord Injruy
09/24
10/24
WAKING, NCT04166721: WaKING: Wnt and checKpoint INhibition in Gastric Cancer

Active, not recruiting
1/2
52
Europe
Atezolizumab, DKN-01
Royal Marsden NHS Foundation Trust
Metastatic Esophageal Cancer, Metastatic Gastric Cancer
03/25
12/25
Iintune-1, NCT04420884 / 2022-000528-39: A Study of Dazostinag as Single Agent and Dazostinag in Combination With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors

Active, not recruiting
1/2
374
Europe, Canada, Japan, US, RoW
Dazostinag, TAK-676, Pembrolizumab, Platinum, 5-fluorouracil
Takeda, Takeda Development Center Americas, Inc. (TDC Americas)
Solid Neoplasms
01/26
01/26
FIH, NCT04104776 / 2020-004952-14: A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

Recruiting
1/2
275
Europe, US, RoW
Tulmimetostat, DZR123, Enzalutamide
Novartis Pharmaceuticals
Advanced Solid Tumor, Diffuse Large B Cell Lymphoma, Lymphoma, T-Cell, Mesothelioma, Malignant, Prostatic Neoplasms, Castration-Resistant, Endometrial Cancer, Ovarian Clear Cell Carcinoma, Metastatic Castration-resistant Prostate Cancer
02/30
02/30
NCT03840460: A Prospective Translational Tissue Collection Study in Early and Advanced Pancreatic Ductal Adenocarcinoma and Pancreatic Neuroendocrine Tumours to Enable Further Disease Characterisation and the Development of Potential Predictive and Prognostic Biomarkers

Recruiting
N/A
200
Europe
Royal Marsden NHS Foundation Trust
Pancreatic Adenocarcinoma
01/23
01/23
NCT03857529: Improving Stroke Motor Control With Non-invasive Brain Stimulation and Functional Electrical Stimulation

Recruiting
N/A
15
US
transcranial direct current stimulation and electrical stimulator
MetroHealth Medical Center
Stroke, Rehabilitation, Hand
08/26
08/26
TRACC, NCT04050345: Tracking Mutations in Cell Free Tumour DNA to Predict Relapse in Early Colorectal Cancer

Recruiting
N/A
1000
Europe
Royal Marsden NHS Foundation Trust
Colorectal Cancer
07/29
07/31
MAGnET, NCT06702384: Molecular Analysis of Gastric and OEsophageal Cancers STudy

Withdrawn
N/A
300
Europe
biopsy
Royal Marsden NHS Foundation Trust
Adenocarcinoma Esophagus, Adenocarcinoma of the Stomach, Adenocarcinoma - GEJ, Squamous Cell Car. - Esophagus
05/27
05/30
NCT05866003: tDCS + CCFES-mediated Functional Task Practice for Post-stroke Upper Extremity Hemiplegia

Recruiting
N/A
63
US
Active conventional tDCS montage plus CCFES, Active unconventional tDCS montage plus CCFES, Sham tDCS plus CCFES, CCFES with Occupational Therapy
MetroHealth Medical Center
Stroke, Upper Extremity Paresis, Hemiplegia
04/28
04/28
Fracchiolla, Nicola
NCT03250338 / 2017-001600-29: Study Investigating the Efficacy of Crenolanib With Chemotherapy vs Chemotherapy Alone in R/R FLT3 Mutated AML

Recruiting
3
322
Europe, Canada, US
Crenolanib, Crenolanib besylate, Cytarabine, Mitoxantrone, Placebo Oral Tablet, Fludarabine, Idarubicin, G-CSF
Arog Pharmaceuticals, Inc.
Relapsed/Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations
10/24
10/24
NCT04342962 / 2020-001543-94: Tagraxofusp in Patients With CD123+ or With BPDCN-IPh-like Acute Myeloid Leukemia

Terminated
2
25
Europe
tagraxofusp
Gruppo Italiano Malattie EMatologiche dell'Adulto, Stemline Therapeutics, Inc., Fondazione GIMEMA (Gruppo Italiano Malattie EMatologiche dell'Adulto) Franco Mandelli Onlus
Acute Myeloid Leukemia
01/24
01/24
NCT05306301 / 2022-000633-17: Ponatinib Plus Chemotherapy in Acute Lymphoblastic Leukemia Patients

Recruiting
2
32
Europe
Ponatinib
Gruppo Italiano Malattie EMatologiche dell'Adulto, Incyte Biosciences International Sàrl, Docteur-Yersin 12, 1110 Morges, Switzerland, FONDAZIONE GIMEMA
Chemotherapy, Leukemia, Acute Lymphoblastic
02/25
07/28
1621-QLG-LG, NCT03755856: Long-term Outcomes for Acute Myeloid Leukemia Patients

Recruiting
N/A
343
Europe, RoW
Questionnaire
Gruppo Italiano Malattie EMatologiche dell'Adulto, European Organisation for Research and Treatment of Cancer - EORTC
Acute Myeloid Leukemia
06/21
12/22
NCT04352556: COVID19-hematological Malignancies: the Italian Hematology Alliance

Recruiting
N/A
250
Europe
Ospedale di Circolo - Fondazione Macchi
SARS-CoV-2 Infection, Hematological Malignancies
10/22
10/22
GIMEMA 2320, NCT04589728: Prospective and Retrospective Observational Evaluation of Real World Outcome of Unfit AML Patients Treated With the Combination Venetoclax Plus Hypomethylating Agents, Under the Italian Law No.648/96

Recruiting
N/A
104
Europe
Venetoclax plus HMA
Gruppo Italiano Malattie EMatologiche dell'Adulto
Acute Myeloid Leukemia
12/22
12/23
NCT04460950: Observational Study for the Evaluation of Incidence of Familial AML/MDSs in Patients With Myeloid Neoplasms

Recruiting
N/A
237
Europe
Gruppo Italiano Malattie EMatologiche dell'Adulto
Acute Myeloid Leukemia, Familial Acute Myeloid Leukemia, Myelodysplastic Syndromes
03/25
03/25
NCT03318770: Post-Frontline Sequential Treatment of Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Recruiting
N/A
60
Europe
Dasatinib and blinatumomab
Gruppo Italiano Malattie EMatologiche dell'Adulto
Acute Lymphoblastic Leukemia
05/24
05/24
IMPACT STREAM, NCT06459024: Master Framework For Relapse or Refractory Acute Myeloid Leukemia

Recruiting
N/A
4000
Europe
Registration into the STREAM platform
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS, Hospital Vall d'Hebron, Cyprus Institute of Neurology and Genetics, European LeukemiaNet, Fundacion Para La Investigacion Hospital La Fe, Ostedusche Hematology and Oncology Study Group, Ospedale Pediatrico Bambin Gesù, Czech Lymphoma Study Group, Charite University, Berlin, Germany, Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León, University of Bologna, Hannover Medical School, German Society for Pediatric Oncology and Hematology GPOH gGmbH, Toscana Life Sciences Sviluppo s.r.l., Lithuanian University of Health Sciences, Gruppo Italiano Malattie EMatologiche dell'Adulto, Time.Lex
Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory
07/32
07/32
Drenth, Joost PH
CAMARO, NCT02900443: Mycophenolate Mofetil Versus Azathioprine in Treatment Naive Autoimmune Hepatitis

Active, not recruiting
4
70
Europe
Mycophenolate mofetil, Azathioprine
Radboud University Medical Center, Leiden University Medical Center
Autoimmune Hepatitis
06/23
06/23
NATiV3, NCT04849728: A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( )

Recruiting
3
1000
Europe, Canada, US, RoW
IVA337, Lanifibranor, Placebo
Inventiva Pharma
NASH - Nonalcoholic Steatohepatitis
09/25
09/26
POSITANO, NCT05281328 / 2021-003764-27: A Trial to Assess the Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With PLD

Active, not recruiting
2/3
71
Europe, US
CAM2029, octreotide subcutaneous depot, Placebo
Camurus AB, Camurus AB
Polycystic Liver Disease
02/25
08/27
ATLAS, NCT05500157: Assessment of Treatment With Laparoscopic Fenestration or Aspiration Sclerotherapy for Large Symptomatic Hepatic Cysts

Recruiting
N/A
70
Europe
aspiration sclerotherapy versus laparoscopic fenestration
Radboud University Medical Center
Liver Cyst, Polycystic Liver Disease, Autosomal Dominant Polycystic Kidney, Autosomal Dominant Polycystic Liver Disease
10/23
10/24
NCT02173080: Development and Assessment of The Polycystic Liver Disease Questionnaire (PLD-Q).

Completed
N/A
594
US
PLD-Q
Mayo Clinic
Polycystic Liver Disease
03/24
03/24
PLD, NCT04645251: Polycystic Liver Disease Registry (UK)

Recruiting
N/A
500
Europe
Portsmouth Hospitals NHS Trust, Radboud University Medical Center
Polycystic Liver Disease
12/30
12/30
Agostoni, Carlo
PROBIOS2021, NCT06052540: Probiotic Supplementation in Children Affected by Upper Respiratory Infections

Active, not recruiting
N/A
128
Europe
Probiotic supplement, Ofmom SynterAct BIMBI, Placebo
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Upper Respiratory Tract Infection
06/23
06/24
Zinzani, Pier Luigi
BRUIN CLL-313, NCT05023980: A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Active, not recruiting
3
250
Europe, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Bendamustine, Treanda, Treakisym, Ribomustin, Levact, Rituximab, Rituxan, MabThera, Truxima, Riabni, Ruxience
Loxo Oncology, Inc., Eli Lilly and Company
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
05/25
08/26
BRUIN-MCL-321, NCT04662255 / 2020-004553-72: Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)

Recruiting
3
500
Europe, Canada, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib, Imbruvica, Acalabrutinib, Calquence, Zanubrutinib, Brukinsa
Loxo Oncology, Inc., Eli Lilly and Company
Lymphoma, Mantle-Cell
01/27
04/28
ECHELON-3, NCT04404283 / 2020-002686-33: Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL

Hourglass Jan 2023 - Dec 2023 : From:ECHELON-3 trial in combination with brentuximab vedotin and rituximab for r/r DLBCL
Active, not recruiting
3
241
Europe, Canada, US, RoW
Brentuximab vedotin, Rituximab, Lenalidomide, Placebo
Seagen, a wholly owned subsidiary of Pfizer
Diffuse Large B-cell Lymphoma
11/25
11/25
BRUIN CLL-322, NCT04965493 / 2021-000043-49: A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Active, not recruiting
3
600
Europe, Canada, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Venetoclax, Venclexta, Venclyxto, Rituximab, Rituxan, MabThera, Truxima, Riabni, Ruxience
Loxo Oncology, Inc., Eli Lilly and Company
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
04/26
01/27
BRUIN-CLL-314, NCT05254743 / 2021-003206-41: A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Active, not recruiting
3
650
Europe, Canada, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib
Loxo Oncology, Inc., Eli Lilly and Company
Chronic Lymphocytic Leukemia, Leukemia, Lymphocytic, Leukemia, B-cell, Small Lymphocytic Lymphoma
06/25
01/28
RITZ, NCT05735834: Comparison Between Rituximab Plus Zanubrutinib Versus Rituximab Monotherapy in Untreated SMZL Patients

Recruiting
3
120
Europe
Rituximab, Truxima, Zanubrutinib, Brukinsa
International Extranodal Lymphoma Study Group (IELSG)
Splenic Marginal Zone Lymphoma
05/29
05/29
NCT04442022 / 2020-000605-84: A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) with or Without Selinexor in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma

Recruiting
2/3
501
Europe, US, RoW
Selinexor (combination therapy), Placebo matching for Selinexor (combination therapy), Rituximab (combination therapy), Gemcitabine (combination therapy), Dexamethasone (combination therapy), Cisplatin (combination therapy), Selinexor (continuous therapy), Placebo matching for Selinexor (continuous therapy)
Karyopharm Therapeutics Inc
Relapsed/refractory Diffuse Large B-cell Lymphoma
12/25
12/25
LORELY, NCT06918912 / 2022-001147-24: Study of Loncastuximab Tesirine in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) or High-Grade B-Cell Lymphoma (HGBCL) Following CAR-T Therapy Failure

Recruiting
2
50
Europe
Loncastuximab Tesirine (Anti-CD19 Antibody-Drug Conjugate)
Istituto Clinico Humanitas
Diffuse Large B-Cell Lymphoma, High-grade B-cell Lymphoma (HGBCL), B-Cell Lymphoma Treatment, Relapsed or Refractory Lymphoma
03/25
06/27
TELLOMAK, NCT03902184 / 2018-003969-33: IPH4102 Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma

Checkmark Preliminary efficacy data from TELLOMAK trial for Sezary syndrome at ASH 2022
Dec 2022 - Dec 2022: Preliminary efficacy data from TELLOMAK trial for Sezary syndrome at ASH 2022
Checkmark Data from stage 2 cohort of TELLOMAK trial for mycosis fungoides
Sep 2022 - Sep 2022: Data from stage 2 cohort of TELLOMAK trial for mycosis fungoides
Checkmark Preliminary efficacy data from stage 1 of TELLOMAK trial for mycosis fungoides at ICML 2021
More
Active, not recruiting
2
170
Europe, US
IPH4102, lacutamab
Innate Pharma
Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Mycosis Fungoides/Sezary Syndrome
10/23
01/26
SGN35-032, NCT04569032 / 2020-002336-74: A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression

Active, not recruiting
2
82
Europe, US, RoW
brentuximab vedotin, ADCETRIS, cyclophosphamide, doxorubicin, prednisone
Seagen, a wholly owned subsidiary of Pfizer
Peripheral T-cell Lymphoma
05/24
12/25
DALY 2-EU, NCT04844866 / 2020-003908-14: Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients

Active, not recruiting
2
168
Europe, RoW
MB-CART2019.1, R-GemOx or BR plus polatuzumab vedotin, Rituximab, Gemcitabine, Oxaliplatin, Polatuzumab vedotin, Bendamustine, Rituximab
Miltenyi Biomedicine GmbH, ICON plc
Diffuse Large B-cell Lymphoma
01/25
07/29
FIL_MOZART, NCT06492837: Study With Mosunetuzumab and Zanubrutinib in R/R Follicular Lymphoma Patients

Not yet recruiting
2
56
Europe
Mosunetuzumab in combination with Zanubrutinib, LUNSUMIO in combination with BRUSINKA
Fondazione Italiana Linfomi - ETS
Follicular Lymphoma
09/28
09/33
NCT06854653: A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCL

Recruiting
2
115
Europe, US, RoW
PTX-100
Prescient Therapeutics, Ltd.
CTCL
01/28
06/28
MOLTO, NCT04082897 / 2018-005028-40: ObinutuzuMab AtezOlizumab and VenetocLax in RichTer transfOrmation

Active, not recruiting
2
28
Europe
Obinutuzumab 25 MG/ML [Gazyva], Atezolizumab 60 MG/ML [Tecentriq], Venetoclax Oral Tablet
Niguarda Hospital
CLL Transformation
09/26
12/26
FIL_Tisle-HL, NCT05977673: Efficacy and Safety of Frontline Tislelizumab in Patients With de Novo Hodgkin Lymphoma Unsuitable for Standard Frontline Chemotherapy

Recruiting
2
28
Europe
Tislelizumab
Fondazione Italiana Linfomi - ETS
Hodgkin Lymphoma
11/27
11/29
SIDNEY, NCT04669171 / 2020-003999-40: A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma

Recruiting
1/2
60
Europe, US
EO2463, lenalidomide, Revlimid, rituximab, MabThera
Enterome
Follicular Lymphoma, Marginal Zone Lymphoma
05/26
05/32
ALPHA-2, NCT04416984: Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (ALPHA2)

Recruiting
1/2
160
Europe, Canada, US, RoW
ALLO-501A, ALLO-647, Fludarabine, Cyclophosphamide
Allogene Therapeutics
Relapsed or Refractory Large B Cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small Lymphocytic Lymphoma
01/25
05/29
FIH, NCT04104776 / 2020-004952-14: A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

Recruiting
1/2
275
Europe, US, RoW
Tulmimetostat, DZR123, Enzalutamide
Novartis Pharmaceuticals
Advanced Solid Tumor, Diffuse Large B Cell Lymphoma, Lymphoma, T-Cell, Mesothelioma, Malignant, Prostatic Neoplasms, Castration-Resistant, Endometrial Cancer, Ovarian Clear Cell Carcinoma, Metastatic Castration-resistant Prostate Cancer
02/30
02/30
NCT02576496: Study of Tinostamustine, First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies

Completed
1
106
Europe, US
Tinostamustine, EDO-S101
Mundipharma Research Limited
Hematological Malignancies, Multiple Myeloma, Hodgkin's Lymphoma, Cutaneous T Cell Lymphoma
05/23
11/23
POSS, NCT06734078: An Italian Multicenter Retrospective Observational Study to Assess the Clinical Characteristics and the Outcome of Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma Treated with Polatuzumab Vedotin Plus Rituximab (± Bendamustine) Under Named Patient Programme

Active, not recruiting
N/A
100
Europe
IRCCS Azienda Ospedaliero-Universitaria di Bologna
DLBCL - Diffuse Large B Cell Lymphoma
12/25
12/25
VAX4FRAIL, NCT04848493: National Project on Vaccines, COVID-19 and Frail Patients

Recruiting
N/A
1300
Europe
COVID-19 vaccines
Azienda Unità Sanitaria Locale Reggio Emilia, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Istituto Clinico Humanitas, IRCCS San Raffaele, Regina Elena Cancer Institute, Istituto Nazionale per le Malattie Infettive "Lazzaro Spallanzani" IRCCS, University of Roma La Sapienza, Fondazione IRCCS Policlinico San Matteo di Pavia, Istituti Fisioterapici Ospitalieri, Istituto Tumori Giovanni Paolo II, BARI, Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta, IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy, IRCCS Azienda Ospedaliero-Universitaria di Bologna
COVID-19, Solid Tumor, Hematologic Diseases, Neurologic Disorder, Rheumatic Diseases
07/21
04/22
LYMPH-OS, NCT06814925: Italian Study of Patients with Lymphoma

Recruiting
N/A
1500
Europe
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Lymphoma
08/26
08/26
RETRO-LYMPH, NCT06781437: Retrospective Observational Study of Italian Cohort of Lymphoma Patients

Recruiting
N/A
5500
Europe
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Lymphoproliferative Syndrome, Autoimmune, Lymphoma
12/27
12/27
PRIMICI, NCT06781450: Study in Patients with Relapsed/refractory Primary Mediastinal Lymphoma Treated with Pembrolizumab or Nivolumab in Combination with Brentuximab Vedotin in a Real-life Context

Recruiting
N/A
50
Europe
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Primary Mediastinal B Cell Lymphoma
12/25
12/25
PIXBRIDGE, NCT06760936: Pixantrone as Bridging Therapy to Allogenic Transplant or CAR-T Cell Therapy in DLBCL Patients

Active, not recruiting
N/A
15
Europe
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Diffuse Large B Cell Lymphoma (DLBCL)
12/25
12/25
MEPI-AGE, NCT06761274: Study of Epigenetic and Inflammatory Markers of Accelerated Biological Ageing in the Follow up of Patients With Hodgkin's Lymphoma

Recruiting
N/A
200
Europe
peripheral blood sampling
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Hodgkin Lymphoma in Remission
09/25
09/25
SilOs, NCT06720870: An Italian Multicenter Retrospective Observational Study to Assess Effectiveness and Safety of Siltuximab for Patients with Castleman's Disease Treated in Italy in a Real-life Context

Recruiting
N/A
65
Europe
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Castleman Disease
01/25
01/25
AMICO, NCT06814405: Safety and Feasibility of a Multidisciplinary Programme of Integrated Hospital-home Management with Early Discharge of Patients with Haematological Malignancies Undergoing High-dose Chemotherapy in Hospital

Recruiting
N/A
100
Europe
Home patient management, Hospital patient management
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Haematological Malignancy
12/25
12/25
NCT03797170: Design of New Personalized Therapeutic Approaches for Diffuse Large B-cell Lymphoma

Active, not recruiting
N/A
50
Europe
Gut microbiota samples
University of Bologna
Diffuse Large B Cell Lymphoma
07/23
12/23
NCT06299553: Study to Evaluate the Effectiveness of Tafasitamab in Combination With Lenalidomide Followed by Tafasitamab Monotherapy in Relapsed or Refractory Diffuse Large B-cell Lymphoma Non-transplant Eligible Patients in Italy (PRO-MIND)

Recruiting
N/A
200
Europe
Incyte Biosciences Italy S.r.l, Advice Pharma Group srl
DLBCL - Diffuse Large B Cell Lymphoma
06/25
06/27
LNH012, NCT06026644: Health-Related Quality of Life Outcomes in Patients With Aggressive B-Cell Lymphomas Treated With CAR-T Cell Therapy in Real Life

Active, not recruiting
N/A
170
Europe
Gruppo Italiano Malattie EMatologiche dell'Adulto
DLBCL - Diffuse Large B Cell Lymphoma
02/24
04/26
NCT06441214: Retrospective-prospective Study to Evaluate Treatment Management and Outcomes of Patients With Waldenström's Macroglobulinemia (WM) Treated in Italy According to the Zanubrutinib (Brukinsa®) Compassionate Use Program (CUP) and in Common Practice Following Commercial Approval.

Not yet recruiting
N/A
125
Europe
Zanubrutinib
Fondazione Italiana Linfomi - ETS
Waldenström's Macroglobulinemia (WM)
07/26
07/26
HL-SIP, NCT06733987: Immunological Senescence Phenotype as a Resistance Profile to Pembrolizumab in Patients With Relapsed/Refractory Hodgkin's Lymphoma

Recruiting
N/A
40
Europe
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Hodgkin Lymphoma
02/27
02/27
CLIO, NCT06720701: Development of Prognostic Models for Response and Toxicity to CAR-T Cell Therapy in Patients with Relapsed/refractory Non Hodgkin's Lymphoma.

Not yet recruiting
N/A
125
Europe
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Non-Hodgkin Lymphoma
12/26
12/26
ZanOs, NCT06823960: Study to Assess Effectiveness and Safety of Zanubrutinib for Patients with Marginal Zone Lymphoma Treated in Italy Under the Named Patient Program (NPP)

Recruiting
N/A
59
Europe
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Marginal Zone Lymphoma(MZL)
06/25
06/25
FIL_CTCL, NCT06588868: Systemic Therapies in the Treatment of Cutaneous T-cell Lymphoma

Not yet recruiting
N/A
400
Europe
Fondazione Italiana Linfomi - ETS, Takeda
Cutaneous T Cell Lymphoma, Cutaneous T-Cell Lymphoma/Mycosis Fungoides, Cutaneous T-Cell Lymphoma/Sezary Syndrome
07/26
07/26
BRAF, NCT06781515: Assessment of Disease Burden in Hairy Cell Leukemia

Recruiting
N/A
45
Europe
Peripheral and BM blood sample
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Hairy Cell Leukemia
11/25
11/25
FIL_MOGA, NCT06113081: Real World Experience With Mogamulizumab in the Treatment of Cutaneous T-cell Lymphoma

Recruiting
N/A
150
Europe
Fondazione Italiana Linfomi - ETS
Cutaneous T Cell Lymphoma, Cutaneous T-Cell Lymphoma/Mycosis Fungoides, Cutaneous T-Cell Lymphoma/Sezary Syndrome
05/25
07/25
MarZoLyOss, NCT06806488: Study to Assess Clinical Characteristics and Outcome of Patients with Marginal Zone Lymphomas

Recruiting
N/A
160
Europe
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Marginal Zone B Cell Lymphoma
10/25
10/25
Endemato, NCT06851702: Observational Study for the Evaluation of Immune-mediated Endocrinological Adverse Events in Patients with Hematological Malignancies and Subjected to Treatment with Immune-checkpoint Inhibitors

Recruiting
N/A
100
Europe
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Hematological Malignancies
12/25
12/25
ACCELERATE, NCT02817997: International Registry for Patients With Castleman Disease

Recruiting
N/A
1000
US
University of Pennsylvania, EUSA Pharma, Inc., Castleman Disease Collaborative Network, Food and Drug Administration (FDA)
Castleman Disease, Castleman's Disease, Giant Lymph Node Hyperplasia, Angiofollicular Lymph Hyperplasia, Angiofollicular Lymph Node Hyperplasia, Angiofollicular Lymphoid Hyperplasia, GLNH, Hyperplasia, Giant Lymph Node, Lymph Node Hyperplasia, Giant
09/26
09/26
MicroCar, NCT05725720: Role of the Gut Microbiome in the Outcome of Diffuse Large B-Cell Lymphoma Patients Treated With CAR-T Cell Therapy

Recruiting
N/A
90
Europe
Gut microbiome analysis
University of Bologna, Associazione Italiana per la Ricerca sul Cancro, IRCCS Azienda Ospedaliero-Universitaria di Bologna
Diffuse Large B Cell Lymphoma
07/27
12/27
NCT05700149: Integrated Molecular and Clinical Profiling to Improve Disease Characterization and Outcome Prediction in Nodal Marginal Zone Lymphoma

Recruiting
N/A
300
Europe, US, RoW
International Extranodal Lymphoma Study Group (IELSG)
Nodal Marginal Zone Lymphoma
12/26
12/26
Sabatino, Antonio Di
RIDARTII, NCT04587141: Clinical Burden of Anemia in Inflammatory Bowel Disease: Therapeutic Trial

Recruiting
3
300
Europe
Sucrosomial iron, Sideral, Ferric Gluconate, Ferrlecit, Ferric carboxymaltose, Ferinject
IRCCS Policlinico S. Matteo, Italian Group for Inflammatory Bowel Diseases (IG-IBD)
Iron Deficiency Anemia, Inflammatory Bowel Diseases
06/23
06/23
ABX464-105, NCT05507203: ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1

Recruiting
3
612
Europe, Canada, US, RoW
ABX464, Obefazimod, Placebo
Abivax S.A.
Ulcerative Colitis
03/25
04/25
ABTECT, NCT05535946: - Maintenance

Recruiting
3
1050
Europe, Canada, Japan, US, RoW
ABX464, Obefazimod, Placebo
Abivax S.A.
Ulcerative Colitis
01/26
01/30
NCT06598943: A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis

Recruiting
2
140
Europe, Canada, Japan, US, RoW
Eltrekibart, LY3041658, Mirikizumab, LY3074828, Placebo
Eli Lilly and Company
Ulcerative Colitis, Ulcerative Colitis Chronic
12/27
09/28
ENHANCE-CD, NCT06456593: Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease

Recruiting
2
212
Europe, US, RoW
Obefazimod, Placebo
Abivax S.A.
Moderately to Severely Active Crohn Disease
12/26
04/28
NCT05353985 / 2020-005438-14: A Study of TAK-062 in Treatment of Active Celiac Disease in Participants Attempting a Gluten-Free Diet

Completed
2
153
Europe, Canada, US
TAK-062, Simulated Inadvertent Gluten Exposure (SIGE) Gluten-Bar, TAK-062 Placebo, Simulated Inadvertent Gluten Exposure (SIGE) Gluten-free Bar
Takeda
Celiac Disease
11/24
11/24
PROSPER, NCT06505304: AI-enabled Endoscopic Prediction of Post-operative Recurrence in Crohn's Disease

Recruiting
N/A
225
Europe, Canada, RoW
Colonoscopy, Intestinal biopsies, Confocal laser endomicroscopy, Intestinal ultrasound, Stool, Blood, Saliva, Clinical follow-up
University College Cork, The Leona M. and Harry B. Helmsley Charitable Trust
Crohn Disease
10/25
05/26
MONET, NCT06709209: AI-driven Narrow-band Imaging Score for Disease Assessment and Outcome Prediction in Ulcerative Colitis

Recruiting
N/A
300
Europe, Japan, RoW
Colonoscopy after bowel cleansing, Intestinal biopsies, blood sampling, Stool, Clinical follow-up
University College Cork, Olympus
Ulcerative Colitis (UC)
09/26
09/27
SENIOR, NCT05853874: Development of Sustainable Eating Pattern to Limit Malnutrition in Older Adults

Not yet recruiting
N/A
128
NA
Nutrition intervention (dietary protocol), Hospital standard of care
University of Pavia, Fondazione Salvatore Maugeri, Fondazione IRCCS Policlinico San Matteo di Pavia
Malnutrition, Sarcopenia
01/26
01/26
 

Download Options